1. Steinberg D, Pearson TA, Kuller LH. Alcohol and atherosclerosis.
Ann Intern Med 1991;114:967–76.
2. Reiser S. Effect of dietary sugars on metabolic risk factors
associated with heart disease. Nutr Health 1985;3:203–16.
3. Szanto S, Yudkin J. The effect of dietary sucrose on blood lipids
serum insulin, platelet adhesiveness and body weight in human volunteers. Postgrad Med
J 1969;45:602–7.
4. Hollenbeck CB. Dietary fructose effects on lipoprotein metabolism and
risk for coronary artery disease. Am J Clin Nutr 1993;58(5 Suppl):800S–9S.
5. Naismith DJ, Akinyanju PA, Szanto S, Yudkin J. The effect in
volunteers of coffee and decaffeinated coffee on blood glucose, insulin, plasma lipids and
some factors involved in blood clotting. Nutr Metab 1970;12:144–51.
6. Anderson JW, Gustafson NJ. High-carbohydrate, high-fiber diet.
Postgrad Med 1987;82:40–55 [review].
7. Glore SR, van Treeck D, Knehans AW, Guild M. Soluble fiber and serum
lipids: a literature review. J Am Diet Assoc 1994;94:425–36.
8. Cominacini L, Zocca I, Garbin U, et al. Long-term effect of a low-fat,
high carbohydrate diet on plasma lipids of patients affected by familial endogenous
hypertriglyceridemia. Am J Clin Nutr 1988;48:57–65.
9. West C, Sullivan DR, Katan MB, et al. Boys from populations with
high-carbohydrate intake have higher fasting triglyceride levels than boys from populations
with high-fat intake. Am J Epidemiol 1990;131:271–82.
10. Ullmann D, Connor WE, Hatcher LF, et al. Will a high-carbohydrate,
low-fat diet lower plasma lipids and lipoproteins without producing hypertriglyceridemia?
Arterioscler Thromb 1991;11:1059–67.
11. Patsch JR, Miesenbock G, Hopferwieser T, et al. Relation of
triglyceride metabolism and coronary artery disease. Studies in the postprandial state.
Arterioscler Thromb 1992;12:1336–45.
12. Ryu JE, Howard G, Craven TE, et al. Postprandial triglyceridemia and
carotid atherosclerosis in middle-aged subjects. Stroke 1992;23:823–8.
13. Zoppo A, Maggi FM, Catapano AL. A successful dietary treatment fails
to normalize plasma triglyceride postprandial response in type IV patients.
Atherosclerosis 1999;146:19–23.
14. Consensus Development Panel. Treatment of hypertriglyceridemia.
JAMA 1984;251:1196–200.
15. Burr ML, Fehily AM, Gilbert JF, et al. Effects of changes in fat,
fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial
(DART). Lancet 1989;ii:757–61.
16. Kromhout D, Bosschieter EB, de Lezenne Coulander C. The inverse
relation between fish consumption and 20-year mortality from coronary heart disease. N
Engl J Med 1985;312:1205–9.
17. Ascherio A, Rimm EB, Stampfer MJ, et al. Dietary intake of marine n-3
fatty acids, fish intake, and the risk of coronary disease among men. N Engl J Med
1995;332:977–82.
18. Merrill JR, Holly RG, Anderson RL, et al. Hyperlipemic response of
young trained and untrained men after a high fat meal. Arteriosclerosis
1989;9:217–23.
19. Cowan LD, Wilcosky T, Criqui MH, et al. Demographic, behavioral,
biochemical, and dietary correlates of plasma triglycerides. Arteriosclerosis
1985;5:466–80.
20. Despres J-P, Tremblay A, Leblanc C, Bouchard C. Effect of the amount
of body fat on the age-associated increase in serum cholesterol. Prev Med
1988;17:423–31.
21. Prichard BN, Smith CCT, Ling KLE, Betteridge DJ. Fish oils and
cardiovascular disease. BMJ 1995;310:819–20 [editorial/review].
22. Von Schacky C, Fischer S, Weber PC. Long-term effects of dietary
marine omega-3 fatty acids upon plasma and cellular lipids, platelet function, and eicosanoid
formation in humans. J Clin Invest 1985;76:1626–31.
23. Leaf A, Weber PC. Cardiovascular effects of n-3 fatty acids. N
Engl J Med 1988;318:549–57.
24. Adler AJ, Holub BJ. Effect of garlic and fish-oil supplementation on
serum lipid and lipoprotein concentrations in hypercholesterolemic men. Am J Clin
Nutr 1997;65:445–50.
25. Haglund O, Luostarinen R, Wallin R, et al. The effects of fish oil on
triglycerides, cholesterol, fibrinogen and malondialdehyde in humans supplemented with vitamin
E. J Nutr 1991;121:165–9.
26. Oostenbrug GS, Mensink RP, Hornstra G. A moderate in vivo vitamin E
supplement counteracts the fish-oil-induced increase in in vitro oxidation of human
low-density lipoproteins. Am J Clin Nutr 1993;57:827S.
27. Arsenio L, Bodria P, Magnati G, et al. Effectiveness of long-term
treatment with pantethine in patients with dyslipidemia. Clin Ther
1986;8:537–45.
28. Avogaro P, Bon GB, Fusello M. Effect of pantethine on lipids,
lipoproteins and apolipoproteins in man. Curr Ther Res 1983;33:488–93.
29. Maggi GC, Donati C, Criscuoli G. Pantethine: a physiological
lipomodulating agent, in the treatment of hyperlipidemias. Curr Ther Res
1982;32:380–6.
30. Brown WV. Niacin for lipid disorders. Postgrad Med
1995;98:183–93 [review].
31. Head KA. Inositol hexaniacinate: a safer alternative to niacin.
Altern Med Rev 1996;1:176–84 [review].
32. Murray M. Lipid-lowering drugs vs. inositol hexaniacinate. Am J
Natural Med 1995;2(8):9–12 [review].
33. Bierenbaum ML, Fleischman AI, Raichelson RI. Long term human studies
on the lipid effects of oral calcium. Lipids 1972;7:202–6.
34. Carlson LA, Olsson AG, Oro L, Rossner S. Effects of oral calcium upon
serum cholesterol and triglycerides in patients with hyperlipidemia. Atherosclerosis
1971;14:391–400.
35. Lee NA, Reasner CA. Beneficial effect of chromium supplementation on
serum triglyceride levels in NIDDM. Diabetes Care 1994;17:1449–52.
36. Abraham AS, Brooks BA, Eylath U. The effects of chromium
supplementation on serum glucose and lipids in patients with and without non-insulin-dependent
diabetes. Metabolism 1992;41:768–71.
37. Thomas VL, Gropper SS. Effect of chromium nicotinic acid
supplementation on selected cardiovascular disease risk factors. Biol Trace Elem Res
1996;55:297–305.
38. Rabinowitz MB, Gonick HC, Levin SR, Davidson MB. Effects of chromium
and yeast supplements on carbohydrate and lipid metabolism in diabetic men. Diabetes
Care 1983;6:319–27.
39. Uusitupa MI, Kumpulainen JT, Voutilainen E, et al. Effect of
inorganic chromium supplementation on glucose tolerance, insulin response, and serum lipids in
noninsulin-dependent diabetics. Am J Clin Nutr 1983;38:404–10.
40. Offenbacher EG, Pi-Sunyer FX. Beneficial effect of chromium-rich
yeast on glucose tolerance and blood lipids in elderly subjects. Diabetes
1980;29:919–25.
41. Offenbacher EG, Rinko CJ, Pi-Sunyer FX. The effects of inorganic
chromium and brewer’s yeast on glucose tolerance, plasma lipids, and plasma chromium in
elderly subjects. Am J Clin Nutr 1985;42:454–61.
42. Roeback JR Jr, Hla KM, Chambless LE, Fletcher RH. Effects of chromium
supplementation on serum high-density lipoprotein cholesterol levels in men taking
beta-blockers. A randomized, controlled trial. Ann Intern Med
1991;115:917–24.
43. Wilson BE, Gondy A. Effects of chromium supplementation on fasting
insulin levels and lipid parameters in healthy, non-obese young subjects. Diabetes Res
Clin Pract 1995;28:179–84.
44. Thomas VL, Gropper SS. Effect of chromium nicotinic acid
supplementation on selected cardiovascular disease risk factors. Biol Trace Elem Res
1996;55:297–305.
45. Pola P, Savi L, Grilli M, et al. Carnitine in the therapy of
dyslipidemic patients. Curr Ther Res 1980;27:208–16.
46. Abdel-Aziz MT, Abdou MS, Soliman K, et al. Effect of carnitine on
blood lipid pattern in diabetic patients. Nutr Rep Int 1984;29:1071–9.
47. Anonymous. Carnitine, clue or cure? Lancet
1982;2:1027–8.
48. Yamashita K, Kawai K, Itakura M. Effect of fructo-oligosaccharides on
blood glucose and serum lipids in diabetic subjects. Nutr Res 1984;4:961–6.
49. Jackson KG, Taylor GRJ, Clohessy AM, Williams CM. The effect of the
daily intake of inulin on fasting lipid, insulin and glucose concentrations in middle-aged men
and women. Br J Nutr 1999;82:23–30.
50. Roberfroid M. Dietary fibre, inulin and oligofructose. A review
comparing their physiological effects. Crit Rev Food Sci Nutr 1993;33:103–48
[review].
51. Davidson MH, Synecki C, Maki KC, Drennen KB. Effects of dietary
inulin in serum lipids in men and women with hypercholesterolaemia. Nutr Res
1998;3:503–17.
52. Luo J, Rizkalla SW, Alamowitch C, et al. Chronic consumption of
short-chain fructooligosaccharides by health subjects decreased basal hepatic glucose
production but had no effect on insulin-stimulated glucose metabolism. Am J Clin Nutr
1996;63:939–45.
53. Pedersen A, Sandstrom B, van Amelsvoort JMM. The effect of ingestion
of inulin on blood lipids and gastrointestinal symptoms in healthy females.
1997;78:215–22.
54. van Dokkum W, Wezendonk B, Srikumar TS, van den Heuvel EG. Effect of
nondigestible oligosaccharides on large-bowel functions, blood lipid concentrations and
glucose absorption in young healthy male subjects. Eur J Clin Nutr
1999;53:1–7.
55. Gouni-Berthold I, Berthold HK. Policosanol: clinical pharmacology and
therapeutic significance of a new lipid-lowering agent. Am Heart J
2002;143:356–65 [review].
56. Mirkin A, Mas R, Martinto M, et al. Efficacy and tolerability of
policosanol in hypercholesterolemic postmenopausal women. Int J Clin Pharmacol Res
2001;21:31-41.
57. Castano G, Mas R, Fernandez L et al. Effects of policosanol 20 versus
40 mg/day in the treatment of patients with type II hypercholesterolemia: A 6-month
double-blind study. Int J Clin Pharmacol Res 2001;21:43–57.
58. Mas R, Castano G, Illnait J, et al. Effects of policosanol in
patients with type II hypercholesterolemia and additional coronary risk factors. Clin
Pharmacol Ther 1999;65:439–47.
59. Torres O, Agramonte AJ, Illnait J, et al. Treatment of
hypercholesterolemia in NIDDM with policosanol. Diabetes Care
1995;18:393–7.
60. Canetti M, Moreira M, Mas R, et al. A two-year study on the efficacy
and tolerability of policosanol in patients with type II hyperlipoproteinaemia. Int J Clin
Pharmacol Res 1995;15:159–65.
61. Aneiros E, Calderson B, Más R, et al. Effect of successive dose
increases of policosanol on the lipid profile and tolerability of treatment. Curr Ther
Res 1993;54:304–12.
62. Pons P, Rodríquez M, Más R, et al. One-year efficacy and
safety of policosanol in patients with type II hypercholesterolemia. Curr Ther Res
1994;55:1084–92.
63. Castano G, Canetti M, Moreira M, et al. Efficacy and tolerability of
policosanol in elderly patients with type II hypercholesterolemia: a 12-month study. Curr
Ther Res 1995;56:819–23.
64. Castano G, Tula L, Canetti M, et al. Effects of policosanol in
hypertensive patients with type II hypercholesterolemia. Curr Ther Res
1996;57:691–5.
65. Fernandez JC, Mas R, Castano G, et al. Comparison of the efficacy,
safety and tolerability of policosanol versus fluvastatin in elderly hypercholesterolaemic
women. Clin Drug Invest 2001;21:103–13.
66. Castano G, Mas R, Fernandez JC, et al. Efficacy and tolerability of
policosanol compared with lovastatin in patients with type II hypercholesterolemia and
concomitant coronary risk factors. Curr Ther Res 2000;61:137–46.
67. Alcocer L, Fernandez L, Campos E, Mas Ferreiro R. A comparative study
of policosanol Versus acipimox in patients with type II hypercholesterolemia.Int J Tissue
React 1999;21:85–92.
68. Crespo N, Illnait J, Mas R, et al. Comparative study of the efficacy
and tolerability of policosanol and lovastatin in patients with hypercholesterolemia and
noninsulin dependent diabetes mellitus. Int J Clin Pharmacol Res
1999;19:117–27.
69. Castano G, Mas R, Arruzazabala ML, et al. Effects of policosanol and
pravastatin on lipid profile, platelet aggregation and endothelemia in older
hypercholesterolemic patients. Int J Clin Pharmacol Res 1999;19:105–16.
70. Ortensi G, Gladstein J, Valli H, et al. A comparative study of
policosanol versus simvastatin in elderly patients with hypercholesterolemia. Curr Ther
Res 1997;58:390–401.
71. Benitez M, Romero C, Mas R, et al. A comparative study of policosanol
versus pravastatin in patients with type II hypercholesterolemia. Curr Ther Res
1997;58:859–67.
72. Earnest CP, Almada AL, Mitchell TL. High-performance capillary
electrophoresis-pure creatine monohydrate reduces blood lipids in men and women. Clin
Sci 1996;91:113–8.
73. Volek JS, Duncan ND, Mazzetti SA, et al. No effect of heavy
resistance training and creatine supplementation on blood lipids. Int J Sport Nutr Exerc
Metab 2000;10:144–56.
74. Agarwal RC, Singh SP, Saran RK, et al. Clinical trial of gugulipid
new hypolipidemic agent of plant origin in primary hyperlipidemia. Indian J Med Res
1986;84:626–34.
75. Warshafsky S, Kamer R, Sivak S. Effect of garlic on total serum
cholesterol: A meta-analysis. Ann Int Med 1993;119(7)599–605.
76. Silagy C, Neil A. Garlic as a lipid-lowering agent—a
meta-analysis. J R Coll Phys London 1994;28(1):39–45.
77. Neil HAW, Silagy CA, Lancaster T, et al. Garlic powder in the
treatment of moderate hyperlipidaemia: A controlled trial and a meta-analysis. J R Coll
Phys 1996;30:329–34.
78. McCrindle BW, Helden E, Conner WT. Garlic extract therapy in children
with hypercholesterolemia. Arch Pediatr Adolesc Med 1998;152:1089–94.
79. Isaacsohn JL, Moser M, Stein EA, et al. Garlic powder and plasma
lipids and lipoproteins. Arch Intern Med 1998;158:1189–94.
80. Berthold HK, Sudhop T, von Bergmann K. Effect of a garlic oil
preparation on serum lipoproteins and cholesterol metabolism. JAMA
1998;279:1900–2.
81. Lawson L. Garlic oil for hypercholesterolemia—negative results.
Quart Rev Natural Med Fall 1998;185–6.
82. Garlic powder for hyperlipidemia—analysis of recent negative
results. Quart Rev Natural Med Fall 1998;187–9.
83. Asgary S, Naderi GH, Sarrafzadegan N, et al. Antihypertensive and
antihyperlipidemic effects of Achillea wilhelmsii. Drugs Exp Clin Res
2000;26:89–93.
84. Sharma RD, Raghuram TC, Dayasagar Rao V. Hypolipidaemic effect of
fenugreek seeds. A clinical study. Phyother Res 1991;5:145–7.
85. Sharma RD, Sarkar DK, Hazra B, et al. Hypolipidaemic effect of
fenugreek seeds: A chronic study in non-insulin dependent diabetic patients. Phytother
Res 1996;10:332–4.
86. Sharma RD, Raghuram TC, Rao NS. Effect of fenugreek seeds on blood
glucose and serum lipids in type I diabetes. Eur J Clin Nutr 1990;44:301–6.
87. Prasanna M. Hypolipidemic effect of fenugreek: A clinical study.
Indian J Pharmacol 2000;32:34–6.
88. Jenkins DJA, Wolever TMS, Vidgen E, et al. Effect of psyllium in
hypercholesterolemia at two monounsaturated fatty acid intakes. Am J Clin Nutr
1997;65:1524–33.
89. Ganji V, Kies CV. Pysllium husk fiber supplementation to the diets
rich in soybean or coconut oil: Hypocholesterolemic effect in healthy humans. Int J Food
Sci Nutr 1996;47:103–10.
90. Davidson MH, Maki KC, Kong JC, et al. Long-term effects of consuming
foods containing psyllium seed husk on serum lipids in subjects with hypercholesterolemia.
Am J Clin Nutr 1998;67:367–76.
91. Tsubono Y, Tsugane S. Green tea intake in relation to serum lipid
levels in middle-aged Japanese men and women. Ann Epidemiol 1997;7:280–4.
92. Imai K, Nakachi K. Cross sectional study of effects of drinking green
tea on cardiovascular and liver diseases. BMJ 1995;310:693–6.
93. Wang J, Lu Z, Chi J, et al. Multicenter clinical trial of the serum
lipid-lowering effects of a Monascus purpureus (red yeast) rice preparation from
traditional Chinese medicine. Curr Ther Res 1997;58:964–77.
94. Heber D, Lembertas A, Lu QY, et al. An analysis of nine proprietary
Chinese red yeast rice dietary supplements: implications of variability in chemical profile
and contents. J Altern Complement Med 2001;7:133–9.
95. Kubo K, Nanba H. Anti-hyperliposis effect of maitake fruit body
(Grifola frondosa). I. Biol Pharm Bull 1997;20:781–5.